AACR19: HER2 targeted CAR-T cell therapy shows promise in advanced sarcomas patients

Written by Mike Gregg, Future Science Group

Image credit: Dylan Burnette and Jennifer Lippincott-Schwartz, NIH A combination therapy that uses both chemotherapy and CAR-T cells engineered to target the HER2 protein has been found to be safe and showed clinical response in paediatric and adult patients that have advanced HER2+ sarcoma. The results from the Phase I clinical trial was recently presented at the AACR Annual Meeting 2019 (March 29–April 3, GA, USA). Currently children and adults that have recurrent or refractory sarcomas have very limited treatment options. Generally curative chemotherapy regimens are given, however, the chances of successful treatment are low and the therapies can be toxic....

To view this content, please register now for access

It's completely free